<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="pt" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40172432</article-id><article-id pub-id-type="pmc">PMC12013735</article-id><article-id pub-id-type="other">00501</article-id><article-id pub-id-type="doi">10.36660/abc.20240526</article-id><article-categories><subj-group subj-group-type="heading"><subject>Carta Cient&#x000ed;fica</subject></subj-group></article-categories><title-group><article-title>Sobrevida em Pacientes com Fenoc&#x000f3;pia de Brugada. S&#x000e9;rie de Casos</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1694-6920</contrib-id><name><surname>Fonseca</surname><given-names>Luis Mariano De la Torre</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><role>An&#x000e1;lise estat&#x000ed;stica</role><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2389-4812</contrib-id><name><surname>Cede&#x000f1;o</surname><given-names>Robert Alarc&#x000f3;n</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-4663-3856</contrib-id><name><surname>Bello</surname><given-names>Lileska Andre&#x000ed;na Hernandez</given-names></name><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1876-5197</contrib-id><name><surname>D&#x000ed;az-Heredia</surname><given-names>Juan</given-names></name><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise estat&#x000ed;stica</role><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-1571-3672</contrib-id><name><surname>Quezada</surname><given-names>Diego Milton Pulla</given-names></name><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-8108-3750</contrib-id><name><surname>Castro</surname><given-names>Rub&#x000e9;n Andr&#x000e9;s Guam&#x000e1;n</given-names></name><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3096-8114</contrib-id><name><surname>Juan-Salvadores</surname><given-names>Pablo</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgname">Hospital Comandante Manuel Fajardo</institution>
<institution content-type="orgdiv1">Unit Care</institution>
<addr-line>
<named-content content-type="city">La Habana</named-content>
</addr-line>
<country country="CU">Cuba</country>
<institution content-type="original">Hospital Comandante Manuel Fajardo &#x02013; Unit Care, La Habana &#x02013; Cuba</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">Institute of Cardiovascular Health</institution>
<institution content-type="orgdiv1">Isac-Med</institution>
<institution content-type="orgdiv2">Interventional Cardiology Unit</institution>
<addr-line>
<named-content content-type="city">Guayaquil</named-content>
</addr-line>
<country country="EC">Equador</country>
<institution content-type="original">Institute of Cardiovascular Health (Isac-Med) &#x02013; Interventional Cardiology Unit, Guayaquil &#x02013; Equador</institution>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="orgname">General Hospital of the North of Guayaquil</institution>
<addr-line>
<named-content content-type="city">Guayaquil</named-content>
</addr-line>
<country country="EC">Equador</country>
<institution content-type="original">General Hospital of the North of Guayaquil, Guayaquil &#x02013; Equador</institution>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="orgname">Universidad Catolica de Santiago de Guayaquil</institution>
<addr-line>
<named-content content-type="city">Guayaquil</named-content>
</addr-line>
<country country="EC">Equador</country>
<institution content-type="original">Universidad Catolica de Santiago de Guayaquil &#x02013; Cardriology, Guayaquil &#x02013; Equador</institution>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="orgname">Institute of Cardiovascular Health</institution>
<addr-line>
<named-content content-type="city">Guayaquil</named-content>
</addr-line>
<country country="EC">Equador</country>
<institution content-type="original">Institute of Cardiovascular Health &#x02013; Cardiology, Guayaquil &#x02013; Equador</institution>
</aff><aff id="aff6">
<label>6</label>
<institution content-type="orgname">South Clinic Hospital</institution>
<addr-line>
<named-content content-type="city">Guayaquil</named-content>
</addr-line>
<country country="EC">Equador</country>
<institution content-type="original">South Clinic Hospital &#x02013; Emergency, Guayaquil &#x02013; Equador</institution>
</aff><aff id="aff7">
<label>7</label>
<institution content-type="orgname">University Hospital of Vigo</institution>
<institution content-type="orgdiv1">Cardiology Department</institution>
<addr-line>
<named-content content-type="city">Vigo</named-content>
</addr-line>
<country country="ES">Espanha</country>
<institution content-type="original">University Hospital of Vigo &#x02013; Cardiology Department, Vigo &#x02013; Espanha</institution>
</aff><aff id="aff8">
<label>8</label>
<institution content-type="orgname">Galicia Sur Health Research Institute</institution>
<addr-line>
<named-content content-type="city">Vigo</named-content>
</addr-line>
<country country="ES">Espanha</country>
<institution content-type="original">Galicia Sur Health Research Institute, Vigo &#x02013; Espanha</institution>
</aff><author-notes><corresp id="c01">
<label>Correspond&#x000ea;ncia</label>: Luis Mariano De la Torre Fonseca &#x02022; Hospital Comandante Manuel Fajardo &#x02013; Unit Care &#x02013; Calle D, entre Zapata y 29,No. 803 La Habana 10400 &#x02013; Cuba E-mail: <email>marianotorre33@gmail.com</email>
</corresp><fn fn-type="edited-by"><p><bold>Editor respons&#x000e1;vel pela revis&#x000e3;o:</bold> Mauricio Scanavacca</p></fn><fn fn-type="COI-statement"><p><bold>Potencial Conflito de Interesse:</bold> N&#x000e3;o h&#x000e1; conflito com o presente artigo.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>122</volume><issue>3</issue><elocation-id>e20240526</elocation-id><history><date date-type="received"><day>25</day><month>4</month><year>2024</year></date><date date-type="rev-recd"><day>07</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Este &#x000e9; um artigo de acesso aberto distribu&#x000ed;do sob os termos da licen&#x000e7;a de atribui&#x000e7;&#x000e3;o pelo Creative Commons</license-p></license></permissions><kwd-group><kwd>S&#x000ed;ndrome de Brugada</kwd><kwd>Canais I&#x000f4;nicos</kwd><kwd>Relatos de Casos</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="6"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introdu&#x000e7;&#x000e3;o</title><p>A fenoc&#x000f3;pia de Brugada (FB) se refere a uma situa&#x000e7;&#x000e3;o na qual os padr&#x000f5;es eletrocardiogr&#x000e1;ficos caracter&#x000ed;sticos da s&#x000ed;ndrome de Brugada (SB) s&#x000e3;o temporariamente manifestados, os quais s&#x000e3;o indistingu&#x000ed;veis dos padr&#x000f5;es tipo 1 (coberto) e 2 (sela) da SB. V&#x000e1;rios crit&#x000e9;rios adicionais devem ser considerados para um diagn&#x000f3;stico preciso. Estes incluem a presen&#x000e7;a de uma causa subjacente identific&#x000e1;vel, regress&#x000e3;o do padr&#x000e3;o uma vez que esta causa &#x000e9; corrigida, baixa probabilidade pr&#x000e9;-teste de SB, um resultado negativo de um teste de indu&#x000e7;&#x000e3;o farmacol&#x000f3;gica e um teste gen&#x000e9;tico negativo.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>Atualmente, o verdadeiro mecanismo que causa a FB permanece desconhecido. Entretanto, a eleva&#x000e7;&#x000e3;o do segmento ST poderia ser explicada pelo gradiente transmural resultante da perda da c&#x000fa;pula do potencial de a&#x000e7;&#x000e3;o no epic&#x000e1;rdio e n&#x000e3;o no endoc&#x000e1;rdio ventricular. Esse fen&#x000f4;meno se origina do aumento transit&#x000f3;rio das correntes de sa&#x000ed;da de K (Ito) ou da diminui&#x000e7;&#x000e3;o das correntes de entrada de Ca tipo L e das correntes de pico de Na na fase 1 do potencial de a&#x000e7;&#x000e3;o. V&#x000e1;rias condi&#x000e7;&#x000f5;es cl&#x000ed;nicas revers&#x000ed;veis, como dist&#x000fa;rbios do meio interno, compress&#x000e3;o mec&#x000e2;nica, isquemia e embolia pulmonar, doen&#x000e7;as mioc&#x000e1;rdicas e peric&#x000e1;rdicas, entre outras, constituem suas principais etiologias.<sup><xref rid="B2" ref-type="bibr">2</xref></sup></p><p>At&#x000e9; o momento, o progn&#x000f3;stico da FB varia de acordo com a condi&#x000e7;&#x000e3;o subjacente que a desencadeia e tende a ser mais favor&#x000e1;vel em compara&#x000e7;&#x000e3;o &#x000e0; SB. No entanto, estudos atuais avaliando a sobrevida de pacientes com essa condi&#x000e7;&#x000e3;o s&#x000e3;o escassos. Este estudo teve como objetivo determinar a sobrevida de um grupo de pacientes hospitalizados em nosso centro com o diagn&#x000f3;stico de FB.</p><p>Nosso estudo incluiu 7 pacientes com padr&#x000e3;o eletrocardiogr&#x000e1;fico de Brugada (Tipo 1), baixa probabilidade pr&#x000e9;-teste para SB e condi&#x000e7;&#x000e3;o cl&#x000ed;nica que poderia justificar a presen&#x000e7;a de sua fenoc&#x000f3;pia (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl01.pdf" id="d67e351" content-type="local-data">material suplementar 1</inline-supplementary-material>). Foram aplicados os crit&#x000e9;rios diagn&#x000f3;sticos para FB descritos pelos principais especialistas da &#x000e1;rea (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl02.pdf" id="d67e354" content-type="local-data">material suplementar 2</inline-supplementary-material>); no entanto, devido &#x000e0;s condi&#x000e7;&#x000f5;es hemodin&#x000e2;micas, o teste farmacol&#x000f3;gico com bloqueadores dos canais de s&#x000f3;dio (Classe B) n&#x000e3;o foi poss&#x000ed;vel. Uma vez resolvida a condi&#x000e7;&#x000e3;o de base, a revers&#x000e3;o do padr&#x000e3;o eletrocardiogr&#x000e1;fico foi observada em todos os casos.</p></sec><sec sec-type="results"><title>Resultados</title><p>Foram analisados os resultados de 7 pacientes com diagn&#x000f3;stico de FB internados em um hospital secund&#x000e1;rio durante o per&#x000ed;odo de janeiro de 2018 a dezembro de 2023. O padr&#x000e3;o predominante foi o tipo 1, e foi observada recupera&#x000e7;&#x000e3;o eletrocardiogr&#x000e1;fica completa ap&#x000f3;s tratamento da causa de base (<xref rid="f01" ref-type="fig">Figura 1</xref>). A m&#x000e9;dia de idade foi de 70 anos &#x000b1; 13,5, 57,1% eram do sexo feminino e o hist&#x000f3;rico pessoal mais frequente foi hipertens&#x000e3;o arterial. Al&#x000e9;m disso, infarto do mioc&#x000e1;rdio com supradesnivelamento do segmento ST, choque s&#x000e9;ptico por COVID-19 e dist&#x000fa;rbios de pot&#x000e1;ssio (hipo e hipercalemia) ocorreram em 2 casos cada.</p><p>
<fig position="float" id="f01"><label>Figura 1</label><caption><title>&#x02013; Eletrocardiograma em dois pacientes com FB antes e depois do tratamento. A) Paciente com cetoacidose diab&#x000e9;tica e hipercalemia apresentando FB secund&#x000e1;ria a dist&#x000fa;rbios eletrol&#x000ed;ticos com resolu&#x000e7;&#x000e3;o do padr&#x000e3;o eletrocardiogr&#x000e1;fico ap&#x000f3;s o tratamento. B) Paciente com infarto do mioc&#x000e1;rdio com supradesnivelamento do segmento ST apresentando FB, que se resolveu ap&#x000f3;s terapia fibrinol&#x000ed;tica.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240526-gf01" position="float"/></fig>
</p><p>Em rela&#x000e7;&#x000e3;o &#x000e0; ocorr&#x000ea;ncia de arritmias card&#x000ed;acas durante a interna&#x000e7;&#x000e3;o, 3 pacientes apresentaram epis&#x000f3;dios de fibrila&#x000e7;&#x000e3;o atrial (42,9%), e apenas um paciente apresentou taquicardia ventricular. Em 2 pacientes, o padr&#x000e3;o eletrocardiogr&#x000e1;fico da FB foi acompanhado de QTc maior que 470 ms. A mediana de interna&#x000e7;&#x000e3;o hospitalar foi de 5 dias (ICR 4-6), e 5 pacientes (71,4%) morreram durante a admiss&#x000e3;o (<xref rid="t1" ref-type="table">Tabela 1</xref>). A sobrevida global intra-hospitalar foi de 26,8%, com seguimento mediano de 6 dias (IC 95%: 4,6 - 7,4) (<xref rid="f02" ref-type="fig">Figura 2</xref>).</p><p>
<table-wrap position="float" id="t1"><label>Tabela 1</label><caption><title>&#x02013; Caracter&#x000ed;sticas gerais</title></caption><table frame="hsides" rules="groups"><colgroup width="13%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Vari&#x000e1;veis</th><th rowspan="1" colspan="1">Caso 1</th><th rowspan="1" colspan="1">Caso 2</th><th rowspan="1" colspan="1">Caso 3</th><th rowspan="1" colspan="1">Caso 4</th><th rowspan="1" colspan="1">Caso 5</th><th rowspan="1" colspan="1">Caso 6</th><th rowspan="1" colspan="1">Caso 7</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Idade</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">78</td></tr><tr><td rowspan="1" colspan="1">Sexo</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Masculino</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Masculino</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Masculino</td></tr><tr><td rowspan="1" colspan="1">Hist&#x000f3;ria pessoal</td><td align="center" rowspan="1" colspan="1">DM, obesidade, dislipidemia</td><td align="center" rowspan="1" colspan="1">Doen&#x000e7;a card&#x000ed;aca isqu&#x000ea;mica, HT</td><td align="center" rowspan="1" colspan="1">HT, DM</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o refere</td><td align="center" rowspan="1" colspan="1">HT</td><td align="center" rowspan="1" colspan="1">HT, obesidade</td><td align="center" rowspan="1" colspan="1">HT</td></tr><tr><td rowspan="1" colspan="1">Diagn&#x000f3;stico</td><td align="center" rowspan="1" colspan="1">Hipercalemia</td><td align="center" rowspan="1" colspan="1">IAMCSST</td><td align="center" rowspan="1" colspan="1">Embolia pulmonar</td><td align="center" rowspan="1" colspan="1">IAMCSST e Hipocalemia</td><td align="center" rowspan="1" colspan="1">Choque s&#x000e9;ptico (COVID-19)</td><td align="center" rowspan="1" colspan="1">Choque s&#x000e9;ptico (COVID-19)</td><td align="center" rowspan="1" colspan="1">IAMSST</td></tr><tr><td rowspan="1" colspan="1">QTc longo</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td></tr><tr><td rowspan="1" colspan="1">Arritmias Ventriculares</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td></tr><tr><td rowspan="1" colspan="1">Fibrila&#x000e7;&#x000e3;o atrial</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">Sim</td></tr><tr><td rowspan="1" colspan="1">Revers&#x000e3;o de padr&#x000e3;o (horas)</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="1" colspan="1">Perman&#x000ea;ncia na unidade de terapia intensiva (dias)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Situa&#x000e7;&#x000e3;o na alta</td><td align="center" rowspan="1" colspan="1">Vivo</td><td align="center" rowspan="1" colspan="1">Morto</td><td align="center" rowspan="1" colspan="1">Morto</td><td align="center" rowspan="1" colspan="1">Morto</td><td align="center" rowspan="1" colspan="1">Morto</td><td align="center" rowspan="1" colspan="1">Morto</td><td align="center" rowspan="1" colspan="1">Vivo</td></tr><tr><td rowspan="1" colspan="1">Temperatura (&#x000ba; C)</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">35,5</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">35,5</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">36,5</td></tr><tr><td rowspan="1" colspan="1">K (mmol/L)</td><td align="center" rowspan="1" colspan="1">7,47</td><td align="center" rowspan="1" colspan="1">5.10</td><td align="center" rowspan="1" colspan="1">4,80</td><td align="center" rowspan="1" colspan="1">1,80</td><td align="center" rowspan="1" colspan="1">4,80</td><td align="center" rowspan="1" colspan="1">3,80</td><td align="center" rowspan="1" colspan="1">5.04</td></tr><tr><td rowspan="1" colspan="1">Ca<sup>2+</sup> (mmol/L)</td><td align="center" rowspan="1" colspan="1">0,97</td><td align="center" rowspan="1" colspan="1">0,82</td><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">0,95</td><td align="center" rowspan="1" colspan="1">0,96</td><td align="center" rowspan="1" colspan="1">1.06</td><td align="center" rowspan="1" colspan="1">0,73</td></tr><tr><td rowspan="1" colspan="1">Creatinina (mmol/L)</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">140</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">145</td><td align="center" rowspan="1" colspan="1">334</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">74</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>DM: diabetes mellitus; HT: hipertens&#x000e3;o; IAMCSST: infarto do mioc&#x000e1;rdio com supradesnivelamento do segmento ST; IAMSST: infarto do mioc&#x000e1;rdio sem supradesnivelamento do segmento ST; UTI: unidade de terapia intensiva.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<fig position="float" id="f02"><label>Figura 2</label><caption><title>&#x02013; Sobrevida global em pacientes com FB.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240526-gf02" position="float"/></fig>
</p><p>Atualmente, a maioria das evid&#x000ea;ncias dispon&#x000ed;veis neste campo se limita a relatos de casos e revis&#x000f5;es sistem&#x000e1;ticas. No entanto, as etiologias mais frequentes da FB coincidem com as encontradas nesta investiga&#x000e7;&#x000e3;o: dist&#x000fa;rbios do meio interno, isquemia mioc&#x000e1;rdica e embolia pulmonar, bem como infec&#x000e7;&#x000e3;o por COVID-19.<sup><xref rid="B2" ref-type="bibr">2</xref>-<xref rid="B4" ref-type="bibr">4</xref></sup> As altera&#x000e7;&#x000f5;es causadas por essas doen&#x000e7;as nos canais de sa&#x000ed;da de Ito e nos canais de entrada de Ca e Na na fase 1 do potencial de a&#x000e7;&#x000e3;o,<sup><xref rid="B5" ref-type="bibr">5</xref></sup> bem como nos canais de K na fase 2, desencadeiam outras altera&#x000e7;&#x000f5;es el&#x000e9;tricas, como prolongamento do intervalo QT, fibrila&#x000e7;&#x000e3;o atrial e taquicardia ventricular.</p><p>Nossa pesquisa representa uma das primeiras tentativas de avaliar a sobrevida em pacientes com FB. Os resultados do nosso estudo revelam uma taxa de sobrevida inferior a 30%, significativamente menor quando comparada aos resultados descritos por outros autores.<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref></sup> A apresenta&#x000e7;&#x000e3;o dessa entidade em pacientes com doen&#x000e7;as graves com alta mortalidade, como choque s&#x000e9;ptico, infarto agudo do mioc&#x000e1;rdio e embolia pulmonar de alto risco, provavelmente influenciou esses resultados desfavor&#x000e1;veis. No entanto, a maioria dos pacientes relatados tinha doen&#x000e7;as subjacentes graves; essas condi&#x000e7;&#x000f5;es poderiam explicar a alta mortalidade relatada, impedindo uma reflex&#x000e3;o precisa do progn&#x000f3;stico para todos os pacientes com FB.</p><p>Estudos multic&#x000ea;ntricos com tamanhos de amostra maiores s&#x000e3;o necess&#x000e1;rios para entender melhor a FB. Embora a necessidade de mais investiga&#x000e7;&#x000e3;o persista, certas etiologias, como dist&#x000fa;rbios do meio interno, isquemia mioc&#x000e1;rdica e embolia pulmonar, s&#x000e3;o consistentes na maioria dos casos. Apesar da falta de consenso sobre o mecanismo exato da FB, parece evidente que essas condi&#x000e7;&#x000f5;es contribuem significativamente para seu desenvolvimento. Al&#x000e9;m disso, nossas descobertas sugerem que a sobreviv&#x000ea;ncia de pacientes com FB &#x000e9; relativamente inferior em compara&#x000e7;&#x000e3;o aos resultados de outras investiga&#x000e7;&#x000f5;es. Essa discrep&#x000e2;ncia destaca a import&#x000e2;ncia de abordar de forma abrangente os fatores de risco e comorbidades associados &#x000e0; FB para melhorar os resultados cl&#x000ed;nicos e a qualidade de vida dos pacientes.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Vincula&#x000e7;&#x000e3;o Acad&#x000ea;mica:</bold> N&#x000e3;o h&#x000e1; vincula&#x000e7;&#x000e3;o deste estudo a programas de p&#x000f3;s-gradua&#x000e7;&#x000e3;o.</p></fn><fn fn-type="other"><p><bold>Aprova&#x000e7;&#x000e3;o &#x000c9;tica e Consentimento Informado:</bold> Este estudo foi aprovado pelo Comit&#x000ea; de &#x000c9;tica da Facultad de Ciencias M&#x000e9;dicas Manuel Fajardo sob o n&#x000fa;mero de protocolo 2023/228. Todos os procedimentos envolvidos nesse estudo est&#x000e3;o de acordo com a Declara&#x000e7;&#x000e3;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#x000ed;dos no estudo.</p></fn><fn fn-type="supplementary-material" id="fn_ast1"><p><bold>* Material suplementar:</bold> Para informa&#x000e7;&#x000e3;o adicional do Material Suplementar 1, por favor, <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl01.pdf" id="d67e910" content-type="local-data">clique aqui</inline-supplementary-material>.</p><p>Para informa&#x000e7;&#x000e3;o adicional do Material Suplementar 2, por favor, <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl02.pdf" id="d67e915" content-type="local-data">clique aqui</inline-supplementary-material>.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p><bold>Fontes de Financiamento:</bold> O presente estudo n&#x000e3;o teve fontes de financiamento externas.</p></fn></fn-group><ref-list><title>Refer&#x000ea;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>NR</given-names><suffix>Neto</suffix></name>
<name><surname>Oliveira</surname><given-names>WS</given-names></name>
<name><surname>Mastrocola</surname><given-names>F</given-names></name>
<name><surname>Sacilotto</surname><given-names>L</given-names></name>
</person-group><article-title>Brugada Phenocopy: Mechanisms, Diagnosis, and Implications</article-title><source>J Electrocardiol</source><year>2019</year><volume>55</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jelectrocard.2019.04.017</pub-id><pub-id pub-id-type="pmid">31078108</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c7;inier</surname><given-names>G</given-names></name>
<name><surname>Tse</surname><given-names>G</given-names></name>
<name><surname>Baranchuk</surname><given-names>A</given-names></name>
</person-group><article-title>Brugada Phenocopies: Current Evidence, Diagnostic Algorithms and a Perspective for the Future</article-title><source>Turk Kardiyol Dern Ars</source><year>2020</year><volume>48</volume><issue>2</issue><fpage>158</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.5543/tkda.2020.06118</pub-id><pub-id pub-id-type="pmid">32147660</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>G</given-names></name>
<name><surname>Gottschalk</surname><given-names>BH</given-names></name>
<name><surname>Anselm</surname><given-names>DD</given-names></name>
<name><surname>Benditt</surname><given-names>DG</given-names></name>
<name><surname>Maheshwari</surname><given-names>A</given-names></name>
<name><surname>Sreenivasan</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Relation of the Brugada Phenocopy to Hyperkalemia (from the International Registry on Brugada Phenocopy)</article-title><source>Am J Cardiol</source><year>2018</year><volume>121</volume><issue>6</issue><fpage>715</fpage><lpage>717</lpage><conf-loc>doi</conf-loc><pub-id pub-id-type="doi">10.1016/j.amjcard.2017.12.008</pub-id><pub-id pub-id-type="pmid">29397883</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torre-Fonseca</surname><given-names>LM</given-names></name>
<name><surname>Loor-Cede&#x000f1;o</surname><given-names>F</given-names></name>
<name><surname>Alarc&#x000f3;n-Cede&#x000f1;o</surname><given-names>R</given-names></name>
<name><surname>Barreda-P&#x000e9;rez</surname><given-names>AM</given-names></name>
<name><surname>Reyes-Mora</surname><given-names>AD</given-names></name>
</person-group><article-title>Alteraciones Electrocardiogr&#x000e1;ficas en Pacientes Hospitalizados con COVID-19</article-title><source>Rev Colomb Cardiol</source><year>2022</year><volume>29</volume><issue>6</issue><fpage>640</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.24875/rccar.22000029</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baranchuk</surname><given-names>A</given-names></name>
<name><surname>Nguyen</surname><given-names>T</given-names></name>
<name><surname>Ryu</surname><given-names>MH</given-names></name>
<name><surname>Femen&#x000ed;a</surname><given-names>F</given-names></name>
<name><surname>Zareba</surname><given-names>W</given-names></name>
<name><surname>Wilde</surname><given-names>AA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Brugada Phenocopy: New Terminology and Proposed Classification</article-title><source>Ann Noninvasive Electrocardiol</source><year>2012</year><volume>17</volume><issue>4</issue><fpage>299</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1111/j.1542-474X.2012.00525.x</pub-id><pub-id pub-id-type="pmid">23094876</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Anselm</surname><given-names>DD</given-names></name>
<name><surname>Xu</surname><given-names>G</given-names></name>
<name><surname>Gottschalk</surname><given-names>BH</given-names></name>
</person-group><part-title>Chapter 7 - International Registry and Educational Portal on Brugada Phenocopies</part-title><person-group person-group-type="editor">
<name><surname>Baranchuk</surname><given-names>A</given-names></name>
<role>editor</role>
</person-group><source>Brugada Phenocopy</source><publisher-loc>Amsterdam</publisher-loc><publisher-name>Academic Press</publisher-name><year>2018</year><fpage>61</fpage><lpage>67</lpage></element-citation></ref></ref-list></back><sub-article article-type="translation" id="TRen" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20240526i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Survival in Patients with Brugada Phenocopy. Case Series</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1694-6920</contrib-id><name><surname>Fonseca</surname><given-names>Luis Mariano De la Torre</given-names></name><role>Conception and design of the research and Critical revision of the manuscript for content</role><role>Statistical analysis</role><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2389-4812</contrib-id><name><surname>Cede&#x000f1;o</surname><given-names>Robert Alarc&#x000f3;n</given-names></name><role>Conception and design of the research and Critical revision of the manuscript for content</role><role>Analysis and interpretation of the data</role><xref rid="aff2001" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-4663-3856</contrib-id><name><surname>Bello</surname><given-names>Lileska Andre&#x000ed;na Hernandez</given-names></name><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><xref rid="aff3001" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1876-5197</contrib-id><name><surname>D&#x000ed;az-Heredia</surname><given-names>Juan</given-names></name><role>Acquisition of data</role><role>Statistical analysis</role><xref rid="aff4001" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-1571-3672</contrib-id><name><surname>Quezada</surname><given-names>Diego Milton Pulla</given-names></name><role>Analysis and interpretation of the data</role><role>Writing of the manuscript</role><xref rid="aff5001" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-8108-3750</contrib-id><name><surname>Castro</surname><given-names>Rub&#x000e9;n Andr&#x000e9;s Guam&#x000e1;n</given-names></name><role>Acquisition of data</role><role>Analysis and interpretation of the data</role><xref rid="aff6001" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3096-8114</contrib-id><name><surname>Juan-Salvadores</surname><given-names>Pablo</given-names></name><role>Conception and design of the research and Critical revision of the manuscript for content</role><xref rid="aff7001" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8001" ref-type="aff">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aff1001">
<label>1</label>
<country country="CU">Cuba</country>
<institution content-type="original">Hospital Comandante Manuel Fajardo &#x02013; Unit Care, La Habana &#x02013; Cuba</institution>
</aff><aff id="aff2001">
<label>2</label>
<country country="EC">Ecuador</country>
<institution content-type="original">Institute of Cardiovascular Health (Isac-Med) &#x02013; Interventional Cardiology Unit, Guayaquil &#x02013; Ecuador</institution>
</aff><aff id="aff3001">
<label>3</label>
<country country="EC">Ecuador</country>
<institution content-type="original">General Hospital of the North of Guayaquil, Guayaquil &#x02013; Ecuador</institution>
</aff><aff id="aff4001">
<label>4</label>
<country country="EC">Ecuador</country>
<institution content-type="original">Universidad Catolica de Santiago de Guayaquil &#x02013; Cardriology, Guayaquil &#x02013; Ecuador</institution>
</aff><aff id="aff5001">
<label>5</label>
<country country="EC">Ecuador</country>
<institution content-type="original">Institute of Cardiovascular Health &#x02013; Cardiology, Guayaquil &#x02013; Ecuador</institution>
</aff><aff id="aff6001">
<label>6</label>
<country country="EC">Ecuador</country>
<institution content-type="original">South Clinic Hospital &#x02013; Emergency, Guayaquil &#x02013; Ecuador</institution>
</aff><aff id="aff7001">
<label>7</label>
<country country="ES">Spain</country>
<institution content-type="original">University Hospital of Vigo &#x02013; Cardiology Department, Vigo &#x02013; Spain</institution>
</aff><aff id="aff8001">
<label>8</label>
<country country="ES">Spain</country>
<institution content-type="original">Galicia Sur Health Research Institute, Vigo &#x02013; Spain</institution>
</aff><author-notes><corresp id="c01001">
<label>Mailing Address</label>: Luis Mariano De la Torre Fonseca &#x02022; Hospital Comandante Manuel Fajardo &#x02013; Unit Care &#x02013; Calle D, entre Zapata y 29, No. 803 La Habana 10400 &#x02013; Cuba E-mail: marianotorre33@gmail.com </corresp><fn fn-type="edited-by"><p><bold>Editor responsible for the review:</bold> Mauricio Scanavacca</p></fn><fn fn-type="COI-statement"><p><bold>Potential conflict of interest:</bold> No potential conflict of interest relevant to this article was reported.</p></fn></author-notes><kwd-group><kwd>Brugada Syndrome</kwd><kwd>Ion Channels</kwd><kwd>Case Reports</kwd></kwd-group></front-stub><body><sec sec-type="intro"><title>Introduction</title><p>Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic test.<sup><xref rid="B1" ref-type="bibr">1</xref></sup></p><p>Currently, the true mechanism that causes BP remains unknown. However, ST-segment elevation could be explained by the transmural gradient resulting from the loss of the action potential dome in the epicardium and not in the ventricular endocardium. This phenomenon originates from the transient increase in K outward currents (Ito) or the decrease in L-type Ca inward currents and peak Na currents in phase 1 of the action potential. Various reversible clinical conditions, such as disorders of the internal environment, mechanical compression, ischemia and pulmonary embolism, myocardial and pericardial diseases, among others, constitute its main etiologies.<sup><xref rid="B2" ref-type="bibr">2</xref></sup></p><p>So far, the prognosis of BP varies according to the underlying condition that triggers it and tends to be more favorable compared to BS. However, current studies evaluating the survival of patients with this condition are scarce. This study aimed to determine the survival of a group of patients hospitalized in our center with the diagnosis of BP.</p><p>Our study included 7 patients with the electrocardiographic pattern of Brugada (Type 1), a low pretest probability for BS, and a clinical condition that could justify the presence of its phenocopy. (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl01-en.pdf" id="d67e1132" content-type="local-data">supplementary material 1</inline-supplementary-material>) The diagnostic criteria for BP described by leading experts in the field were applied (<inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl02-en.pdf" id="d67e1135" content-type="local-data">supplementary material 2</inline-supplementary-material>); however, due to hemodynamic conditions, the pharmacological test with sodium channel blockers (Class B) was not possible. Once the underlying condition was resolved, the reversal of the electrocardiographic pattern was observed in all cases.</p></sec><sec sec-type="results"><title>Results</title><p>The results of 7 patients with a diagnosis of BP hospitalized in a secondary hospital during the period from January 2018 to December 2023 were analyzed. The predominant pattern was type 1, and complete electrocardiographic recovery was observed following treatment of the underlying cause (<xref rid="f01001" ref-type="fig">Figure 1</xref>). The mean age was 70 years &#x000b1; 13.5, 57.1% were female, and the most frequent personal history was arterial hypertension. Additionally, ST-segment elevation myocardial infarction, COVID-19 septic shock, and potassium disorders (hypo- and hyperkalemia) occurred in 2 cases each.</p><p>
<fig position="float" id="f01001"><label>Figure 1</label><caption><title>&#x02013; Electrocardiogram in two patients with BP before and after treatment. A) Patient with diabetic ketoacidosis and hyperkalemia presenting with a BP secondary to electrolyte disturbances with resolution of the electrocardiographic pattern following treatment. B) Patient with ST-segment elevation myocardial infarction presenting with a BP, which resolved after fibrinolytic therapy.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240526-gf01-en" position="float"/></fig>
</p><p>Regarding the occurrence of cardiac arrhythmias during hospitalization, 3 patients presented episodes of atrial fibrillation (42.9%), and only one patient exhibited ventricular tachycardia. In 2 patients, the electrocardiographic pattern of BP was accompanied by a QTc greater than 470 ms. The median hospital stay was 5 days (ICR 4-6), and 5 patients (71.4%) died during admission (<xref rid="t1001" ref-type="table">Table 1</xref>). Overall in-hospital survival was 26.8%, with a median follow-up of 6 days (95% CI: 4.6 - 7.4) (<xref rid="f02001" ref-type="fig">Figure 2</xref>).</p><p>
<table-wrap position="float" id="t1001"><label>Table 1</label><caption><title>&#x02013; General characteristics</title></caption><table frame="hsides" rules="groups"><colgroup width="13%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">Case 1</th><th rowspan="1" colspan="1">Case 2</th><th rowspan="1" colspan="1">Case 3</th><th rowspan="1" colspan="1">Case 4</th><th rowspan="1" colspan="1">Case 5</th><th rowspan="1" colspan="1">Case 6</th><th rowspan="1" colspan="1">Case 7</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">78</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td></tr><tr><td rowspan="1" colspan="1">Personal history</td><td align="center" rowspan="1" colspan="1">DM, obesity, dyslipidemia</td><td align="center" rowspan="1" colspan="1">Ischemic heart disease, HT</td><td align="center" rowspan="1" colspan="1">HT, DM</td><td align="center" rowspan="1" colspan="1">No refer</td><td align="center" rowspan="1" colspan="1">HT</td><td align="center" rowspan="1" colspan="1">HT, obesity</td><td align="center" rowspan="1" colspan="1">HT</td></tr><tr><td rowspan="1" colspan="1">Diagnosis</td><td align="center" rowspan="1" colspan="1">Hyperkalemia</td><td align="center" rowspan="1" colspan="1">STEMI</td><td align="center" rowspan="1" colspan="1">Pulmonary embolism</td><td align="center" rowspan="1" colspan="1">STEMI and Hypokalemia</td><td align="center" rowspan="1" colspan="1">Septic shock (COVID-19)</td><td align="center" rowspan="1" colspan="1">Septic shock (COVID-19)</td><td align="center" rowspan="1" colspan="1">NSTEMI</td></tr><tr><td rowspan="1" colspan="1">Long QTc</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Ventricular Arrhythmias</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Atrial Fibrillation</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td rowspan="1" colspan="1">Pattern reversal (hours)</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="1" colspan="1">Intensive Care unit stay (days)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Status at discharge</td><td align="center" rowspan="1" colspan="1">Alive</td><td align="center" rowspan="1" colspan="1">Deceased</td><td align="center" rowspan="1" colspan="1">Deceased</td><td align="center" rowspan="1" colspan="1">Deceased</td><td align="center" rowspan="1" colspan="1">Deceased</td><td align="center" rowspan="1" colspan="1">Deceased</td><td align="center" rowspan="1" colspan="1">Alive</td></tr><tr><td rowspan="1" colspan="1">Temperatur (&#x000ba; C)</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">35.5</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">35.5</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">36.5</td></tr><tr><td rowspan="1" colspan="1">K (mmol/L)</td><td align="center" rowspan="1" colspan="1">7.47</td><td align="center" rowspan="1" colspan="1">5.10</td><td align="center" rowspan="1" colspan="1">4.80</td><td align="center" rowspan="1" colspan="1">1.80</td><td align="center" rowspan="1" colspan="1">4.80</td><td align="center" rowspan="1" colspan="1">3.80</td><td align="center" rowspan="1" colspan="1">5.04</td></tr><tr><td rowspan="1" colspan="1">Ca (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">0.95</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">1.06</td><td align="center" rowspan="1" colspan="1">0.73</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mmol/L)</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">140</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">145</td><td align="center" rowspan="1" colspan="1">334</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">74</td></tr></tbody></table><table-wrap-foot><fn id="TFN1001"><p>DM: diabetes mellitus; HT: hypertension; STEMI: ST-segment elevation myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; ICU: intensive care unit.</p></fn></table-wrap-foot></table-wrap>
</p><p>
<fig position="float" id="f02001"><label>Figure 2</label><caption><title>&#x02013; Overall survival in patients with BP.</title></caption><graphic xlink:href="0066-782X-abc-122-3-e20240526-gf02-en" position="float"/></fig>
</p><p>At present, most of the available evidence in this field is limited to case reports and systematic reviews. Nevertheless, the most frequent etiologies of BP coincide with those found in this investigation: internal milieu disorders, myocardial ischemia, and pulmonary embolism, as well as COVID-19 infection.<sup><xref rid="B2" ref-type="bibr">2</xref>-<xref rid="B4" ref-type="bibr">4</xref></sup> The alterations caused by these diseases on Ito outflow channels and Ca and Na inflow channels in phase 1 of the action potential,<sup><xref rid="B5" ref-type="bibr">5</xref></sup> as well as K channels in phase 2, trigger other electrical alterations such as prolongation of the QT interval, atrial fibrillation, and ventricular tachycardia.</p><p>Our research represents one of the first attempts to evaluate survival in BP patients. The results of our study reveal a survival rate of less than 30%, significantly lower when compared to the results described by other authors.<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref></sup> The presentation of this entity in patients with severe diseases with high mortality, such as septic shock, acute myocardial infarction, and high-risk pulmonary embolism, probably influenced these unfavorable results. However, most of the reported patients had serious underlying diseases; these conditions could explain the high mortality reported, preventing an accurate reflection of the prognosis for all patients with BP.</p><p>Multicenter studies with larger sample sizes are needed to understand BP better. Although the need for further investigation persists, certain etiologies, such as internal milieu disorders, myocardial ischemia, and pulmonary embolism, are consistent in most cases. Despite the lack of consensus on the exact mechanism of BP, it seems evident that these conditions contribute significantly to its development. Furthermore, our findings suggest that the survival of patients with BP is relatively inferior compared to the results of other investigations. This discrepancy highlights the importance of comprehensively addressing the risk factors and comorbidities associated with BP to improve clinical outcomes and quality of life for patients.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Study association:</bold> This study is not associated with any thesis or dissertation work.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This study was approved by the Ethics Committee of the Facultad de Ciencias M&#x000e9;dicas Manuel Fajardo under the protocol number 2023/228. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p></fn><fn fn-type="other" id="fn_ast1_en"><p><bold>* Supplemental Materials:</bold> For additional information Supplemental Material 1, <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl01-en.pdf" id="d67e1482" content-type="local-data">please click here</inline-supplementary-material>.</p><p>For additional information Supplemental Material 2, <inline-supplementary-material xlink:href="0066-782X-abc-122-3-e20240526-suppl02-en.pdf" id="d67e1487" content-type="local-data">please click here</inline-supplementary-material>.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of funding:</bold> There were no external funding sources for this study.</p></fn></fn-group></back></sub-article></article>